STSA NASDAQ
Satsuma Pharmaceuticals, Inc.
1W: +4.8%
1M: +1.9%
3M: +24.0%
1Y: -67.7%
3Y: -95.9%
$1.10
Last traded 2023-06-07 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$0
+0.0% ▲
Gross Profit
$0
+0.0% ▲
Operating Income
-$71M
-38.7% ▼
Net Income
-$69M
-34.9% ▼
EPS (Diluted)
$-2.16
-22.7% ▼
EBITDA
-$58M
-15.2% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 | $0 |
| Gross Margin | — | — | — | — | — |
| R&D Expenses | $6M | $24M | $36M | $38M | $44M |
| SG&A Expenses | $1M | $5M | $12M | $14M | $15M |
| Operating Expenses | $8M | $29M | $48M | $51M | $59M |
| Operating Income | -$8M | -$29M | -$48M | -$51M | -$71M |
| Operating Margin | — | — | — | — | — |
| Interest Expense | $90K | $482K | $350K | $163K | $13K |
| Income Before Tax | -$7M | -$28M | -$48M | -$51M | -$70M |
| Tax Expense | $0 | $340K | $111K | $92K | -$892K |
| Net Income | -$7M | -$29M | -$48M | -$51M | -$69M |
| Net Margin | — | — | — | — | — |
| EPS (Diluted) | $-1.86 | $-4.86 | $-2.74 | $-1.76 | $-2.16 |
| EBITDA | -$7M | -$27M | -$46M | -$51M | -$58M |
| Shares Outstanding | 4M | 6M | 17M | 29M | 32M |